Government of CanadaPublic Health Agency of Canada / Agence de santé publique du Canada
   
Skip all navigation -accesskey z Skip to sidemenu -accesskey x Skip to main menu -accesskey m  
Français Contact Us Help Search Canada Site
PHAC Home Centres Publications Guidelines A-Z Index
Child Health Adult Health Seniors Health Surveillance Health Canada
   
    Public Health Agency of Canada (PHAC)
Canada Communicable Disease Report

 

 

Canada Communicable Disease Report
Volume 28 • ACS-5
1 August 2002

An Advisory Committee Statement (ACS)
National Advisory Committee on Immunization (NACI)*

STATEMENT ON INFLUENZA VACCINATION FOR THE 2002-2003 SEASON

Adobe Downloadable Document PDF (253 KB)

References

  1. Kilbourne ED, Arden NH. Inactivated Influenza Vaccines. In: Plotkin SA, Orenstein WA (eds). Vaccines. Philadelphia: W.B. Saunders Co., 1999, p. 539.

  2. Neuzil KM, Zhu Y, Griffin M et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis 2002;185:147-52.

  3. Longini IM, Koopman JS, Monto AS et al. Estimating household and community transmission parameters for influenza. Am J Epidemiol 1982;115:736-51.

  4. Fox JP, Hall CE, Cooney MK et al. Influenza virus infections in Seattle families, 1975-1979. Am J Epidemiol 1982;116:212-27.

  5. Wright P. Influenza in the family. N Engl J Med 2000;343:1331-332.

  6. Reichert TA, Sugaya N, Fedson DS et al. The Japanese experience with vaccinating school children against influenza. N Engl J Med 2001;344:889-96.

  7. Church DL, Davies HD, Mitton C et al. Clinical and economic evaluation of rapid A virus testing in nursing homes in Calgary, Canada. Clin Infect Dis 2002;34:790-95.

  8. Boivin G, Osterhaus AD, Gaudreau A et al. Role of picornaviruses in flu-like illnesses of adults enrolled in an oseltamivir treatment study who had no evidence of influenza virus infection. J Clin Microbiol 2002;40:330-34.

  9. Effler PV, Ieong MC, Tom T et al. Enhancing public health surveillance for influenza virus by incorporating newly available rapid diagnostic tests. Emerg Infect Dis 2002;8:23-8.

  10. Neuzil KM, Wright PF, Mitchel EF et al. The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr 2000;137:856-64.

  11. Fuller JD, Craven DE, Steger KA et al. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin Infect Dis 1999;28:541-47.

  12. Staprans SI, Hamilton BL, Follansbee SE et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 1995;182:1727-37.

  13. O'Brien WA, Grovit-Ferbas K, Namazi A et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995;86:1082-089.

  14. Glesby MJ, Hoover DR, Farzadegan H, et al. The effect of influenza vaccination on human immunodeficiency virus type 1 load: a randomized, double-blind, placebo-controlled study. J Infect Dis 1996;174:1332-336.

  15. Sullivan PS, Hanson DL, Dworkin MS et al. Effect of influenza vaccination on disease progression among HIV-infected persons. AIDS 2000;14:2781-785.

  16. Tasker SA, Treanor JJ, Paxton WB, Wallace MR. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind placebo-controlled trial. Ann Intern Med 1999;131:430-33.

  17. Fine AD, Bridges CB, DeGuzman AM et al. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis 2001;32:1784-791.

  18. Kroon FP, van Dissel JP, de Jong JC et al. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 2000;18:3040-049.

  19. Miotti PG, Nelson KE, Dallabetta GA et al. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA 1989;262:779-83.

  20. Potter J, Stott DJ, Roberts MA, Elder AG et al. Influenza vaccination of health-care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis 1997:175;1-6.

  21. Wilde JA, McMillan JA, Serwint J et al. Effectiveness of influenza vaccine in health care professionals. A randomized trial. JAMA 1999;281:908-13.

  22. Boersma B, Rhames T, Keegan JM. Additional cost savings of an effective employee influenza program on prevention of nosocomial influenza. Am J Infect Control 1999;27:177-78.

  23. Grotto I, Mandel Y, Green MS et al. Influenza vaccine efficacy in young, healthy adults. Clin Infect Dis 1998;26:913-17.

  24. Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 2001;161:749-59.

  25. Saxen H, Virtanen M. Randomized, placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of health care workers. Pediatr Infect Dis J 1999;18:779-83.

  26. Leighton L, Williams M, Auberg D et al. Sickness absence following a campaign of vaccination against influenza in the workplace. Occup Med Oxf 1996;46:146-50.

  27. White T, Lavoie S, Nettleman MD. Potential cost saving attributable to influenza vaccination of school-aged children. Pediatrics 1999;103:e73.

  28. Demicheli V. Mass influenza vaccination in Ontario: is it worthwhile? CMAJ 2001;164:38-9.

  29. Demicheli V, Rivetti D, Deeks JJ et al. Vaccines for preventing influenza in healthy adults (Cochrane Review). In: The Cochrane Library, Oxford; Issue 2, 2002.

  30. Ahmed F, Singleton JA, Franks AL. Influenza vaccination for healthy young adults. N Engl J Med 2001;345:1543-547.

  31. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2002;51(RR03);1-31.

  32. Deinhard AS, Ogburn P. A/NJ/8/76 influenza vaccination program: effects on maternal health and pregnancy outcome. Am J Obstet Gynecol 1981;140:240-45.

  33. Freeman DW, Barno A. Deaths from Asian influenza associated with pregnancy. Am J Obstet Gynecol 1959;78:1172-175.

  34. Collins SD. Age and sex incidence of influenza and pneumonia morbidity and mortality in the epidemic of 1928-1929 with comparative data for the epidemic of 1918-1919. Public Health Rep 1931;46:1909.

  35. Eickhoff TC, Sherman H, Serfling RE. Observations on excess mortality associated with epidemic influenza. JAMA 1961;176:776.

  36. Mullooly JP, Barker WH, Nolan TF. Risk of acute respiratory disease among pregnant women during influenza A epidemics. Public Health Rep 1986;101:205-11.

  37. Neuzil KM, Reed GW, Mitchel EF et al. Impact of influenza on acute cardiac pulmonary hospitalizations in pregnant women. Am J Epidemiol 1998;148:1094-102.

  38. Aoki FY, Yassi A, Cheang M et al. Effects of acetaminophen on adverse effects of influenza vaccination in health-care workers. Can Med Assoc J 1993;149:1425-430.

  39. Bedard P-M, Gascon G. Fatal outcome of systemic vasculitis following influenza vaccination. Can J Allergy Clin Immun 1999;4:405-06.

  40. Robertson WC. Carbamazepine toxicity after influenza vaccination. Pediatr Neurol 2002;26:61-3.

  41. Lasky T, Terracciano GJ. Magder L et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998;339:1797-802.

  42. McLean M, Duclos P, Jacob P et al. Incidence of Guillain-Barré syndrome in Ontario and Quebec, 1983-1989, using hospital service databases. Epidemiology 1994;5:443-48.

  43. National Advisory Committee on Immunization. Supplementary statement for the 2001-2002 season: influenza vaccination of persons who experienced oculo-respiratory syndrome following previous influenza vaccination. CCDR 2001;27(ACS-7):1-7.

  44. National Advisory Committee on Immunization. Influenza vaccine. In: Canadian Immunization Guide. 6th ed. Ottawa, Ont.: Health Canada 2002;120-27:140-43. (Minister of Public Works and Government Services, Cat. No. H49-8/2002E.)

  45. Duclos P, Arruda H, Dessau JC et al. Immunization survey of non-institutionalized adults - Quebec (as of May 30, 1996). CCDR 1996;22:177-82.

  46. DeWals P, Carbonneau M, Payette H, Niyonsenga T. Influenza and pneumococcal vaccination in long term care facilities in two regions of Quebec. Can J Infect Dis, 1996:7;296-300.

  47. Stevenson CG, McArthur MA, Naus M et al. Prevention of influenza and pneumococcal pneumonia in Canadian long-term care facilities: How are we doing? CMAJ 2001;164:1413-9.

  48. Russell ML. Influenza vaccination in Alberta long-term care facilities. CMAJ 2001;164:1423-427.

  49. Nichol KL, Hauge M. Influenza vaccination of healthcare workers. Infect Control Hosp Epidemiol 1997;18:189-94.

  50. Orr P. Influenza vaccination for health care workers: a duty of care. Can J Infect Dis 2000;11:225-26.

  51. Herwaldt LA. Greek philosophy, medical ethics, and the influenza vaccine. Infect Control Hosp Epidemiol 1993;14:15-16.

  52. Rea E, Upshur R. Semmelweis revisited: the ethics of infection prevention among health care workers. CMAJ 2001;164:1447-448.

  53. McArthur MA, Simor AE, Campbell B et al. Influenza vaccination in long-term-care facilities: structuring programs for success. Infect Control Hosp Epidemiol 1999;20:499-503.

  54. Munoz FM, Campbell J, Atmar RL et al. Influenza A virus outbreak in a neonatal intensive care unit. Pediatr Infect Dis J 1999;18:811-15.

  55. Stone EG, Morton SC, Hulscher ME et al. Interventions that increase the use of adult immunization and cancer screening services: a meta-analysis. Ann Intern Med 2002;136:641-51

  56. Nguyen-Van-Tam J, Granfield R, Pearson J et al. Do influenza epidemics affect patterns of sickness absence among British hospital staff? Infect Control Hosp Epidemiol 1999;20:691-94.

  57. Hammond GW, Cheang M. Absenteeism among hospital staff during an influenza epidemic: implications for immunoprophylaxis. Can Med Assoc J 1984;131:449-52.

  58. Yassi A, Kettner J, Hammond G et al. Effectiveness and cost-benefit of an annual influenza vaccination program for health care workers. Can J Infect Dis 1991;2:101-08.

  59. Stilianakis NI, Perelson AS, Hayden FG. Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. J Infect Dis 1998;1977:863-72.

  60. Saven H, Virtanen M. Randomized, placebo-controlled double blind study on the efficacy of influenza vaccination on absenteeism of health care workers. Pediatr Infect Dis J 1999;18:779-83.

  61. Drinka PJ, Gravenstein S, Schilling M et al. Duration of antiviral prophylaxis during nursing home outbreaks of influenza A. Arch Intern Med 1998;158:2155-59.

  62. Aoki F. Amantadine and Rimantadine. In: Textbook of Influenza. Nicholson KG, Webster RG, Hay AJ, eds. Oxford: Blackwell Science 1998;457-76.

  63. Buxton JA, Skowronski DM, Ng H et al. Previous creatinine levels safely predict amantadine dose for influenza A outbreak control. Can J Infect Dis 2001;12:185-8.

  64. McGeer A, Sitar D, Tamblyn S et al. Use of antiviral prophylaxis in influenza outbreaks in long term care facilities. Can J Infect Dis 2000;11:187-92.

  65. Hirji Z, O'Grady S, Bonham J et al. Utility of Zanamivir for chemoprophylaxis of concomitant influenza A and B infection in a complex continuing care population. CCDR 2001;27:21-24.

  66. Lee C, Loeb M, Phillips A et al. Use of Zanamivir to control an outbreak of Influenza A. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco CA, September 26 1999, Pp. 421. [Abstract 283].

  67. Schilling M, Povinelli L, Krause P et al. Efficacy of Zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine 1998;16:1771-74.

  68. Parker R, Loewen N, Skowronski D. Experience with Oseltamivir in the control of a nursing home influenza B outbreak. CCDR 2001;27:37-40.

  69. Peters PH, Gravenstein S, Norwood P et al. Is oral oseltamivir safe and effective for the prevention of influenza and its complications in frail elderly long-term care residents who have received influenza vaccine? J Fam Pract 2002;51:87.

  70. Monto AS, Robinson DP, Herlocher ML et al. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999;282:31.

  71. Hayden FG, Atmar RL, Schilling M et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999;341:1336-343.

  72. Hayden FG, Gubareva LV, Monto AS et al. Inhaled zanamivir for the prevention of influenza in families: Zanamivir Family Study Group. N Engl J Med 2000;343:1282-289.

  73. Schilling M, Povinelli L, Krause P et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine 1998;16:1771-774.

  74. Lee C, Loeb M, Phillips A et al. Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home. Infect Control Hosp Epidemiol 2000;21:700-04.

  75. Wellivir R, Monto AS, Carewicz O et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001;285:748-54.

  76. McGeer AJ, Lee W, McArthur M et al. Use of zanamivir to control an outbreak of influenza A in a nursing home. [Abstract 609] Clin Infect Dis 2000;31:318.

  77. Peters PH, Gravenstein S, Norwood P et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail elderly population. J Am Geriatr Soc 2001;49:1025-031.

  78. Horadam VW, Sharp JG, Smilack JD et al. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. Ann Intern Med 1981;94:454-58.

[Previous] [Canada Communicable Disease Report]
Last Updated: 2002-08-01 Top
Important Notices